NCT05788484 - A Study of CDX-585 in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

May 21, 2025

Study Completion Date

May 21, 2025

Conditions

Non-small Cell Lung CancerGastric CancerHead and Neck CancerOvarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerBladder Urothelial CarcinomaColorectal CancerEsophageal CancerHepatic CancerRenal Cell CarcinomaCholangiocarcinomaPancreatic CancerOther Solid Tumors

Interventions

DRUG

CDX-585

CDX-585 is administered by infusion every 2 weeks

Trial Locations (4)

10016

Perlmutter Cancer Center at NYU Langone Health, New York

20037

George Washington University Cancer Center, Washington D.C.

34747

AdventHealth Celebration, Celebration

97213

Providence Cancer Institute, Portland